Brind.
From Tandem Diabetes Expands International Availability of Mobi Insulin Delivery System

How will the successful international expansion of Tandem Mobi affect Abbott Laboratories?

Tandem competitor plans future integration with Abbott sensors Tandem Diabetes Care is successfully expanding its market presence for the Tandem Mobi system in numerous international markets. Crucially for Abbott Laboratories, the company is actively developing integrations between its pump system and Abbott's CGM sensors. These integrations are planned to launch in select countries in 2027, representing a significant future competitive challenge to Abbott's market share.

Reported by 1 independent outlet Written Monday
Effect
Strong negative
How direct
2 steps, all reported
When
Over the long term
The story
No new developments lately

How it reaches Abbott Laboratories

Reported by news outlets

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • Tandem Mobi is available in 12 countries outside the United States as of September 2026rutlandherald.com
  • The international markets include Belgium, Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdomrutlandherald.com
  • Additional CGM sensor integrations are in development, including integration with Abbott sensorsrutlandherald.com
  • The planned integrations are expected to begin launching in select countries in 2027rutlandherald.com

Why it matters

For Abbott Laboratories, the successful global expansion of a competitor like Tandem Diabetes Care presents a significant market challenge. The fact that Tandem is actively developing integrations with Abbott's sensor technology means that the company's market leadership and product dominance are being tested by aggressive competitive development.

This competitive pressure is compounded by the fact that the integrations are planned for a 2027 launch in select countries. This timeline requires Abbott to assess its own product roadmap and market strategy to counter the potential introduction of a new, integrated competitor product.

What we don't know yet

  • What are the specific terms of the planned integration between Tandem Mobi and Abbott sensors?
  • How will Abbott Laboratories respond to the impending market presence of a competitor utilizing its technology?

What would change this answer

Tandem Diabetes Care accelerates the launch timeline for the integrationsThe competitive pressure on Abbott Laboratories will increase immediately, forcing a market response.
Abbott Laboratories announces a strategic partnership or counter-product launchThe competitive landscape will become more balanced, mitigating the immediate threat from the competitor.

Reporting

Keep going

The full eventTandem Diabetes Expands International Availability of Mobi Insulin Delivery System Everything aboutAbbott Laboratories

Brind's analysis is written by AI from the reporting linked above and can be wrong. It explains possible effects; it is not investment advice.